Compare Gilead Sciences, Inc. (GILD) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Sunrun Inc — how do they compare? Gilead Sciences, Inc. trades at $133.03 (market cap $163.51B), while Sunrun Inc trades at $12.21 (market cap $3.05B). The key difference: Gilead Sciences, Inc. is far larger — about 53.6× Sunrun Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Sunrun Inc pays none. Which is the better fit depends on your goals.
| GILD | RUN | |
|---|---|---|
Market Cap | $163.51B | $3.05B |
Sector | Health | Technology |
52-Week High | $155.80 | $21.41 |
52-Week Low | $108.22 | $9.07 |
Enterprise Value | $178.05B | $17.24B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Sunrun (RUN) trades at $12.13, down 5.09% over 24 hours, with a bearish technical signal from moving averages. The company shows strong profitability with a 17.88% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights a major partnership with Tesla and Renew Home to create a 16-gigawatt virtual power plant, positioning the company to capitalize on AI data center power demand.
The outlook is mixed; analyst consensus is bullish with a $16.27 price target, but negative operating cash flow and high debt-to-asset ratio of 70.76% pose risks. Upside depends on successful execution of new initiatives and improved cash generation, while volatility may persist amid market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
